Abstract
For the quality evaluation of raw materials, the influence of various types of solvents on the polymorphic crystallization behaviors and dissolution rates of two sources of valsartan (VAL) from China and India was investigated. Samples were prepared by recrystallization from water or organic solvents, such as acetonitrile, acetone and ethanol, using methods with and without heating. Recrystallization behaviors were characterized by differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD). Scanning electron microscopy (SEM) was also used to observe the morphology of samples. The dissolution rate of recrystallized samples in water was evaluated and compared to the original VAL sample. There were significant differences in morphology, crystal structure and dissolution rate among the samples recrystallized using organic solvents. VAL was transformed into another polymorphic form by the solvents and recrystallization conditions. These physical properties of VAL also differed between the two sources of VAL. Thus, the physicochemical differences of raw materials should be carefully considered in early dosage formulation approaches.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adhiyaman, R. and Basu, S. K., Crystal modification of dipyridamole using different solvents and crystallization conditions. Int. J. Pharm., 321, 27–34 (2006).
Barone, C. R., Maresca, L., Natile, G., and Pacifico, C., A new polymorph of dichlorido (1,10-phenanthroline)platinum (II). Inorganica Chim. Acta, 366, 384–387 (2011).
Cappello, B., Maio, C. D., Iervolino, M., and Miro, A., Improvement of solubility and stability of Valsartan by hydroxypropylboldbeta-Cyclodextrin. J. Incl. Phenom. Macrocycl. Chem., 54, 289–294 (2006).
Femi-Oyewo, M. N. and Spring, M. S., Studies on paracetamol crystals produced by growth in aqueous solutions. Int. J. Pharm., 112, 17–28 (1994).
Horst, J. H. T., Geertman, R. M., and Rosmalen, G. M. V., The effect of solvent on crystal morphology. J. Cryst. Growth, 230, 277–284 (2001).
Hu, J., Johnston, K. P., and Williams, R. O., 3rd., Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur. J. Pharm. Sci., 20, 295–303 (2003).
Iqbal, M., Khuroo, A., Batolar, L. S., Tandon, M., Monif, T., and Sharma, P. L., Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Clin. Ther., 32, 588–596 (2010).
Krishnaiah, Ch., Reddy, A. R., Kumar, R., and Mukkanti, K., Stability-indicating UPLC method for determination of Valsartan and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. J. Pharm. Biomed. Anal., 53, 483–489 (2010).
Kitamura, M. and Ishizu, T., Kinetic effect of L-phenylalanine on growth processof L-glutamic acid polymorph. J. Crystal Growth, 192, 225–235 (1998).
Kumar, K. V., Arunkumar, N., Verma, P. R. P., and Rani, C., Preparation and in vitro characterization of valsartan solid dispersions using skimmed milk powder as carrier. Int. J. Pharm. Tech. Res., 1, 431–438 (2009).
Li, W.-J., Shi, E.-W., Zhong, W.-Z., and Yin, Z.-W., Growth mechanism and growth habit of oxide crystals. J. Crystal Growth, 203, 186–196 (1999).
Mandal, S., Saha, R., Mahanti, B., Fleck, M., and Bandyopadhyay, D., Synthesis, characterization and pseudopolymorphism of a phenoxo-bridged binuclear manganese (III) Schiff base complex. Inorganica Chim. Acta, 387, 1–7 (2012).
Megarry, A. J., Booth, J., and Burley, J., Amorphous trehalose dihydrate by cryogenic milling. Carbohydr. Res., 346, 1061–1064 (2011).
Näther, C., Jeß, I., Havlas, Z., Bolte, M., Nagel, N., and Nick, S., Trimorphism of 4,4-Di(tert.-butyl)-biphenyl: structural, thermodynamic and kinetic aspects. Solid State Sci., 4, 859–871 (2002).
Nokhodchi, A., Bolourtchian, N., and Dinarvand, R., Crystal modification of phenytoin using different solvents and crystallization conditions. Int. J. Pharm., 250, 85–97 (2003).
Park, Y. J., Lee, H. K., Im, Y. B., Lee, W., and Han, H. K., Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion. Arch. Pharm. Res., 33, 1235–1240 (2010).
Pilcer, G., Wauthoz, N., and Amighi, K., Lactose characteristics and the generation of the aerosol. Adv. Drug Deliv. Rev., 64, 233–256 (2012).
Remko, M., Bojarska, J., Ježko, P., Sieroń, L., Olczak, A., and Maniukiewicz, W., Crystal and molecular structure of perindopril erbumine salt. J. Mol. Struct., 997, 103–109 (2011).
Shan, G., Igarashi, K., Noda, H., and Ooshima, H., Control of solvent-mediated transformation of crystal polymorphs using a newly developed batch crystallizer (WWDJ-crystallizer). Chem. Eng. J., 85, 169–176 (2002).
Shekunov, B. Y. and York, P., Crystallization processes in pharmaceutical technologyand drug delivery design. J. Crystal Growth, 211, 122–136 (2000).
Singhal, D. and Curatolo, W., Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. Rev., 56, 335–347 (2004).
Suitchmezian, V., Jess, I., and Näther, C., Investigations on the polymorphism and pseudopolymorphism of triamcinolone diacetate. Int. J. Pharm., 323, 101–109 (2006).
Tapas, A. R., Kawtikwar, P. S., and Sakarkar, D. M., Spherically agglomerated solid dispersions of valsartan to improve solubility, dissolution rate and micromeritic properties. Int. J. Drug Deliv., 2, 304–313 (2010).
Tran, T. T., Tran, P. H., and Lee, B. J., Dissolution-modulating mechanism of alkalizers and polymers in a nanoemulsifying solid dispersion containing ionizable and poorly water-soluble drug. Eur. J. Pharm. Biopharm., 72, 83–90 (2009).
Tran, T. T., Tran, P. H., Choi, H. G., Han, H. K., and Lee, B. J., The roles of acidifiers in solid dispersions and physical mixtures. Int. J. Pharm., 384, 60–66 (2010).
Uchimoto, T., Iwao, Y., Takahashi, K., Tanaka, S., Agata, Y., Iwamura, T., Miyagishima, A., and Itai, S., A comparative study of glycerin fatty acid ester and magnesium stearate on the dissolution of acetaminophen tablets using the analysis of available surface area. Eur. J. Pharm. Biopharm., 78, 492–498 (2011).
Widjaja, E., Kanaujia, P., Lau, G., Ng, W. K., Garland, M., Saal, C., Hanefeld, A., Fischbach, M., Maio, M., and Tan, R. B., Detection of trace crystallinity in an amorphous system using Raman microscopy and chemometric analysis. Eur. J. Pharm. Sci., 42, 45–54 (2011).
Youn, Y.-S., Oh, J. H., Ahn, K. H., Kim, M., Kim, J., and Lee, Y.-W., Dissolution rate improvement of valsartan by low temperature recrystallization in compressed CO2: Prevention of excessive agglomeration. J. Supercrit. Fluids, 59, 117–123 (2011).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tran, T.TD., Tran, P.HL., Park, JB. et al. Effects of solvents and crystallization conditions on the polymorphic behaviors and dissolution rates of valsartan. Arch. Pharm. Res. 35, 1223–1230 (2012). https://doi.org/10.1007/s12272-012-0713-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-012-0713-7